Incyte is expanding into dermatology via Opzelura while facing a looming patent cliff of its core franchise in 2028. The company aims to grow its core business (excluding Jakafi) to $3–4 billion by 2030. New CEO Bill Meury is betting on a commercial turnaround with institutional investors including Vanguard and BlackRock holding major positions.
Cyborg Score Rationale
Incyte achieved a milestone of crossing the $5 billion annual revenue mark with 21% year-over-year growth in 2025. However, the company faces challenges from a looming patent cliff of its core franchise in 2028 and competitive pressure from GSK's Ojjaara in hematology and AbbVie and Lilly products in dermatology.
Top Insights
2025 Revenue of $5.14 billion represents 21% year-over-year growth
2026 guidance ranges $4.77-$4.94B with Jakafi projected at $3.22-$3.27B and Opzelura at $750-790M
January 2026 positive Phase 3 results for tafasitamab in first-line DLBCL with sBLA submission planned for H1 2026
Company enters 2026 with 14 pivotal clinical trials underway and $3.6B in cash
Named Competitors
Ojjaara — Competing JAK inhibitor for myelofibrosis with anemia focus
Rinvoq — JAK inhibitor for dermatology and inflammation indications
Olumiant — Dermatology JAK inhibitor competing with Opzelura
Oncology Portfolio — Broader oncology focus with combination therapy strategies
Recent Developments
(February 2026) Earnings miss and conservative 2026 guidance triggered market correction from $112 to ~$102 per share
(January 2026) Positive Phase 3 results announced for tafasitamab (Minjuvi) in first-line DLBCL; sBLA submission planned for H1 2026
(December 2025) FDA response submitted for Jakafi XR with mid-2026 launch potential; European and Japanese approvals for Minjuvi in follicular lymphoma
Open the full interactive Incyte Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.